

Special Issue

Recent Innovations in Precision Oncology: The Pathway toward a Patient-Tailored Approach

Message from the Guest Editor

Precision oncology has been gaining more and more consideration in the scientific community and represents one of most impactful revolutions in medicine. In this scenario, molecular diagnostics through recently introduced techniques, such as next-generation sequencing (NGS), has become an essential tool for a rapid and accurate analysis of oncological patients' genetic profile when molecularly targeted therapies are planned. On the other side, molecular imaging through different techniques (SPECT/CT, PET/CT, optical imaging) has been employed in the field of precision oncology for the in vivo detection of tumor-associated biomarkers, also in the perspective of combining diagnosis and in therapy in a unique approach, also known as "theranostics". In the present Special Issue, we solicit original research or review articles highlighting the potential and emerging applications of novel technologies in precision oncology, with a particular focus on novel molecular probes for molecular imaging and on the still few explored applications of AI and radiomics.

Guest Editor

Prof. Dr. Luca Filippi

Nuclear Medicine Unit, Santa Maria Goretti Hospital, viale Canova snc,
04100 Latina, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/134997

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).